Posted by Michael Wonder on 27 Apr 2023
Novartis Cosentyx gains positive CHMP opinion for hidradenitis suppurativa
26 April 2023 - Positive opinion paves way for first new treatment option in hidradenitis suppurativa in nearly a decade.
Novartis announced today that the CHMP of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorisation for Cosentyx (secukinumab) in adults with active moderate to severe hidradenitis suppurativa.
